Arcutis Biotherapeutics, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
7
Bullish
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
ARQT
Consensus analyst target of $34.75 is 49% above current price.
⚠ currently unprofitable (-4% margin).
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
BUY
Target $34.75 (+48.8%)
8 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
ARQT
UNH
—
Trailing P/E
27.9×
19.4×
Forward P/E
17.8×
-4.3%
Profit Margin
2.7%
90.2%
Gross Margin
18.8%
-9.3%
ROE
12.2%
81.5%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
1.77
Beta
0.41
—
Price / Book
—
$2.9B
Market Cap
$334.9B
$12 – $32
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →